Celltrion to expand global partnerships at CPHI Worldwide 2025 in Frankfurt

Celltrion said Friday that it will participate in CPHI Worldwide 2025, the world’s largest pharmaceutical and biotechnology exhibition, to be held in Frankfurt, Germany, from Oct. 28 to 30, to strengthen its global partnerships and business networks.

A rendering of Celltrion’s exhibition booth design to be showcased at CPHI Worldwide 2025 in Frankfurt, Germany. (Credit: Celltrion)

Now in its 36th year, CPHI attracts more than 60,000 industry professionals from over 170 countries, serving as a major platform for innovation and collaboration across the pharmaceutical value chain. Celltrion has been operating its own booth at the exhibition since 2022 to raise brand awareness and reinforce partnerships with global players.

This year, the company will install a large 202-square-meter independent booth along the main corridor of the exhibition hall, showcasing its technological capabilities and competitive edge.

The booth will feature both private and open meeting spaces to facilitate networking and discussions with partners, while also offering various interactive events and giveaways to engage visitors and promote the Celltrion brand.

During the three-day event, Celltrion plans to strengthen existing relationships in raw material supply and contract manufacturing (CMO) while actively pursuing new partnership opportunities. With the growing global demand for its expanding product portfolio, the company aims to secure a more stable supply chain and enhance collaboration with competitive international partners.

In 2025, Celltrion has accelerated its global expansion by launching several new biosimilars, including Steqeyma (ingredient: ustekinumab-stba) for autoimmune diseases, Avtozma (ingredient: tocilizumab-anoh), Stoboclo and Osenvelt (ingredient: denosumab-bmwo) for bone disorders, and Omlyclo (ingredient: omalizumab-igec) for dermatologic conditions. The company said it will continue to focus on building strong partnerships to ensure supply stability and boost global sales and marketing capabilities.

Beyond biosimilars, Celltrion also plans to explore new business opportunities in emerging modalities and automation technologies, seeking collaboration with potential partners possessing key expertise in these areas. Through these efforts, the company hopes to identify future growth engines and stay ahead of global industry trends.

“By participating once again in one of the most influential global pharmaceutical and biotech events, we aim to highlight Celltrion’s brand value and technological excellence while expanding our collaborations with leading international companies,” a company official said. “Based on our broadened product portfolio, we will continue to strengthen production infrastructure and pursue strategic partnerships that reinforce our competitiveness and position in the global market.”